Literature for camostat mesilate (S01.151 inhibitor)

(Topics flags: I Inhibitor. To select only the references relevant to a single topic, click the link above. See explanation.)

2020
1. Hoffmann,M., Kleine-Weber,H., Schroeder,S., Kruger,N., Herrler,T., Erichsen,S., Schiergens,T.S., Herrler,G., Wu,N.H., Nitsche,A., Muller,M.A., Drosten,C. and Pohlmann,S.
   SARS-CoV-2 Cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor
   Cell (2020) 181, 271-280. PubMed  Europe PubMed DOI  I
2016
2. Bardou,O., Menou,A., Francois,C., Duitman,J.W., von der Thusen,J.H., Borie,R., Sales,K.U., Mutze,K., Castier,Y., Sage,E., Liu,L., Bugge,T.H., Fairlie,D.P., Konigshoff,M., Crestani,B. and Borensztajn,K.S.
   Membrane-anchored serine protease matriptase is a trigger of pulmonary fibrogenesis
   Am J Respir Crit Care Med (2016) 193, 847-860. PubMed  Europe PubMed DOI  I
3. Kakizoe,Y., Miyasato,Y., Onoue,T., Nakagawa,T., Hayata,M., Uchimura,K., Morinaga,J., Mizumoto,T., Adachi,M., Miyoshi,T., Sakai,Y., Tomita,K., Mukoyama,M. and Kitamura,K.
   A serine protease inhibitor attenuates aldosterone-induced kidney injuries via the suppression of plasmin activity
   J Pharmacol Sci (2016) 132, 145-153. PubMed  Europe PubMed DOI  I
4. Narita,Y., Ueda,M., Uchimura,K., Kakizoe,Y., Miyasato,Y., Mizumoto,T., Morinaga,J., Hayata,M., Nakagawa,T., Adachi,M., Miyoshi,T., Sakai,Y., Kadowaki,D., Hirata,S., Mukoyama,M. and Kitamura,K.
   Combination therapy with renin-angiotensin-aldosterone system inhibitor telmisartan and serine protease inhibitor camostat mesilate provides further renoprotection in a rat chronic kidney disease model
   J Pharmacol Sci (2016) 130, 110-116. PubMed  Europe PubMed DOI  I
2015
5. Ueda,M., Uchimura,K., Narita,Y., Miyasato,Y., Mizumoto,T., Morinaga,J., Hayata,M., Kakizoe,Y., Adachi,M., Miyoshi,T., Shiraishi,N., Kadowaki,D., Sakai,Y., Mukoyama,M. and Kitamura,K.
   The serine protease inhibitor camostat mesilate attenuates the progression of chronic kidney disease through its antioxidant effects
   Nephron (2015) 129, 223-232. PubMed  Europe PubMed DOI  I
6. Yamaya,M., Shimotai,Y., Hatachi,Y., Lusamba Kalonji,N., Tando,Y., Kitajima,Y., Matsuo,K., Kubo,H., Nagatomi,R., Hongo,S., Homma,M. and Nishimura,H.
   The serine protease inhibitor camostat inhibits influenza virus replication and cytokine production in primary cultures of human tracheal epithelial cells
   Pulm Pharmacol Ther (2015) 33, 66-74. PubMed  Europe PubMed DOI  I
7. Zhou,Y., Vedantham,P., Lu,K., Agudelo,J., Carrion,R., Jr., Nunneley,J.W., Barnard,D., Pohlmann,S., McKerrow,J.H., Renslo,A.R. and Simmons,G.
   Protease inhibitors targeting coronavirus and filovirus entry
   Antiviral Res (2015) 116, 76-84. PubMed  Europe PubMed DOI  I
2013
8. Morinaga,J., Kakizoe,Y., Miyoshi,T., Onoue,T., Ueda,M., Mizumoto,T., Yamazoe,R., Uchimura,K., Hayata,M., Shiraishi,N., Adachi,M., Sakai,Y., Tomita,K. and Kitamura,K.
   The antifibrotic effect of a serine protease inhibitor in the kidney
   Am J Physiol Renal Physiol (2013) 305, F173-F181. PubMed  Europe PubMed DOI  I
9. Rowe,S.M., Reeves,G., Hathorne,H., Solomon,G.M., Abbi,S., Renard,D., Lock,R., Zhou,P., Danahay,H., Clancy,J.P. and Waltz,D.A.
   Reduced sodium transport with nasal administration of the prostasin inhibitor camostat in subjects with cystic fibrosis
   Chest (2013) 144, 200-207. PubMed  Europe PubMed DOI  I
10. Shirato,K., Kawase,M. and Matsuyama,S.
    Middle East respiratory syndrome coronavirus infection mediated by the transmembrane serine protease TMPRSS2
    J Virol (2013) 87, 12552-12561. PubMed  Europe PubMed DOI  I
2012
11. Hayata,M., Kakizoe,Y., Uchimura,K., Morinaga,J., Yamazoe,R., Mizumoto,T., Onoue,T., Ueda,M., Shiraishi,N., Adachi,M., Miyoshi,T., Sakai,Y., Tomita,K. and Kitamura,K.
    Effect of a serine protease inhibitor on the progression of chronic renal failure
    Am J Physiol Renal Physiol (2012) 303, F1126-F1135. PubMed  Europe PubMed DOI  I
12. Kitamura,K. and Tomita,K.
    Proteolytic activation of the epithelial sodium channel and therapeutic application of a serine protease inhibitor for the treatment of salt-sensitive hypertension
    Clin Exp Nephrol (2012) 16, 44-48. PubMed  Europe PubMed DOI  I
2011
13. Zhao,J., Wang,J., Dong,L., Shi,H., Wang,Z., Ding,H., Shi,H. and Lu,X.
    A protease inhibitor against acute stress-induced visceral hypersensitivity and paracellular permeability in rats
    Eur J Pharmacol (2011) 654, 289-294. PubMed  Europe PubMed DOI  I
2010
14. Ko,T., Kakizoe,Y., Wakida,N., Hayata,M., Uchimura,K., Shiraishi,N., Miyoshi,T., Adachi,M., Aritomi,S., Konda,T., Tomita,K. and Kitamura,K.
    Regulation of adrenal aldosterone production by serine protease prostasin
    J Biomed Biotechnol (2010) 2010, 793843-793843. PubMed  Europe PubMed DOI  PMC  EPMC  I
15. Takahagi,S., Shindo,H., Watanabe,M., Kameyoshi,Y. and Hide,M.
    Refractory chronic urticaria treated effectively with the protease inhibitors, nafamostat mesilate and camostat mesilate
    Acta Derm Venereol (2010) 90, 425-426. PubMed  Europe PubMed DOI  I
2009
16. Coote,K., Atherton-Watson,H.C., Sugar,R., Young,A., MacKenzie-Beevor,A., Gosling,M., Bhalay,G., Bloomfield,G., Dunstan,A., Bridges,R.J., Sabater,J.R., Abraham,W.M., Tully,D., Pacoma,R., Schumacher,A., Harris,J. and Danahay,H.
    Camostat attenuates airway epithelial sodium channel function in vivo through the inhibition of a channel-activating protease
    J Pharmacol Exp Ther (2009) 329, 764-774. PubMed  Europe PubMed DOI  I
17. Maekawa,A., Kakizoe,Y., Miyoshi,T., Wakida,N., Ko,T., Shiraishi,N., Adachi,M., Tomita,K. and Kitamura,K.
    Camostat mesilate inhibits prostasin activity and reduces blood pressure and renal injury in salt-sensitive hypertension
    J Hypertens (2009) 27, 181-189. PubMed  Europe PubMed DOI  I
2007
18. Ishikura,H., Nishimura,S., Matsunami,M., Tsujiuchi,T., Ishiki,T., Sekiguchi,F., Naruse,M., Nakatani,T., Kamanaka,Y. and Kawabata,A.
    The proteinase inhibitor camostat mesilate suppresses pancreatic pain in rodents
    Life Sci (2007) 80, 1999-2004. PubMed  Europe PubMed DOI  I
2006
19. Ashizawa,N., Hashimoto,T., Miyake,T., Shizuku,T., Imaoka,T. and Kinoshita,Y.
    Efficacy of camostat mesilate compared with famotidine for treatment of functional dyspepsia: Is camostat mesilate effective?
    J Gastroenterol Hepatol (2006) 21, 767-771. PubMed  Europe PubMed DOI  I
20. [YEAR:23-2-2006]Yin,J., Noda,Y. and Yotsuyanagi,T.
    Properties of poly(lactic-co-glycolic acid) nanospheres containing protease inhibitors: camostat mesilate and nafamostat mesilate
    Int J Pharm (23-2-2006) 314, 46-55. PubMed  Europe PubMed DOI  I
2005
21. [YEAR:8-11-2005]Gibo,J., Ito,T., Kawabe,K., Hisano,T., Inoue,M., Fujimori,N., Oono,T., Arita,Y. and Nawata,H.
    Camostat mesilate attenuates pancreatic fibrosis via inhibition of monocytes and pancreatic stellate cells activity
    Lab Invest (8-11-2005) 85, 75-89. PubMed  Europe PubMed DOI  I
22. Ohkoshi,M. and Sasaki,Y.
    Antimetastatic activity of a synthetic serine protease inhibitor, FOY-305 (Foypan)
    In Vivo (2005) 19, 133-136. PubMed  Europe PubMed  I
23. Yin,J., Noda,Y., Hazemoto,N. and Yotsuyanagi,T.
    Distribution of protease inhibitors in lipid emulsions: gabexate mesilate and camostat mesilate
    Chem Pharm Bull (Tokyo) (2005) 53, 893-898. PubMed  Europe PubMed DOI  I
2003
24. Yamasaki,Y., Satomi,S., Murai,N., Tsuzuki,S. and Fushiki,T.
    Inhibition of membrane-type serine protease 1/matriptase by natural and synthetic protease inhibitors
    J Nutr Sci Vitaminol (Tokyo) (2003) 49, 27-32. PubMed  Europe PubMed  I
1995
25. Nakamura,K., Johmura,A., Oda,M., Ino,Y., Uchiyama,H., Ohtani,H., Miyazaki,H., Kurumi,M., Akizawa,Y. and Oka,T.
    [Inhibitory effects of sepimostat mesilate (FUT-187) on the activities of trypsin-like serine proteases in vitro]
    Yakugaku Zasshi (1995) 115, 201-212. PubMed  Europe PubMed  I